MedPath

XIIDRA

XIIDRA

Approved
DIN Number

02471027

Drug Class

Human

Market Date

Feb 12, 2018

Company
HC

bausch & lomb inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02471027
AIG Number0159830001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
S01XA25 LIFITEGRAST
Product Specifications
Dosage FormSolution
Route of AdministrationOphthalmic
AHFS Classification52:08.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

LIFITEGRASTActive
Strength: 5 % / W/V
Monograph: LIFITEGRAST

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.